- ISIN
- US92941V2097
- CUSIP
- 92941V209
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 25, 2018
Highlights
- Market Cap
- $28.06M
- Enterprise Value
- $3.42M
- EPS (TTM)
- -$0.50
- Total Revenue (TTM)
- $454.00K
- Gross Profit (TTM)
- $363.00K
- EBITDA (TTM)
- -$23.76M
- Year Range
- $0.28 - $1.96
- Target Price
- $5.75
- ROA (TTM)
- -82.93%
- ROE (TTM)
- -87.09%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
VYNE Performance Chart
VYNE Therapeutics Inc. (VYNE) is up 13.1% since the beginning of the year. At $1 per share, VYNE is trading 66.5% below its 52-week high of $2. Investors who bought $1,000 worth of VYNE shares 5 years ago would now be looking at an investment worth $10.
Loading charts...
Returns By Period
VYNE Therapeutics Inc. (VYNE) has returned 13.08% so far this year and -34.25% over the past 12 months.
VYNE Therapeutics Inc.
- 1D
- -2.96%
- 1M
- -0.00%
- YTD
- 13.08%
- 6M
- 75.07%
- 1Y
- -34.25%
- 3Y*
- -52.34%
- 5Y*
- -60.58%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
VYNE Monthly Returns History
Based on dividend-adjusted daily data since Jan 25, 2018, VYNE's average daily return is -0.14%, while the average monthly return is -3.53%.
Historically, 37% of months were positive and 63% were negative. The best month was Jun 2025 with a return of +73.7%, while the worst month was Apr 2018 at -78.7%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 13 months.
On a daily basis, VYNE closed higher 45% of trading days. The best single day was Jan 4, 2023 with a return of +73.1%, while the worst single day was Apr 9, 2018 at -76.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.41% | 6.06% | -0.48% | 6.56% | 7.10% | -3.80% | 13.08% | ||||||
| 2025 | -29.85% | 7.23% | -37.30% | -15.82% | -28.57% | 73.68% | -77.84% | -12.34% | 4.52% | 6.18% | 8.35% | 50.52% | -82.68% |
| 2024 | -26.61% | 30.41% | 37.67% | -17.92% | 0.79% | -22.44% | -3.55% | -4.21% | 3.30% | 44.68% | 8.82% | 13.18% | 43.78% |
| 2023 | 73.33% | -28.74% | -7.65% | 70.78% | 19.58% | -34.82% | 13.41% | -6.45% | -7.13% | -24.50% | 8.52% | -29.61% | -13.70% |
| 2022 | -39.09% | -12.75% | 19.92% | -35.39% | -3.00% | -4.54% | 11.11% | -27.49% | -28.79% | 14.57% | -9.00% | -35.51% | -85.29% |
| 2021 | 25.32% | -5.81% | -8.24% | -27.83% | -20.04% | -11.14% | -23.08% | -37.04% | -18.24% | -3.60% | -23.13% | -0.97% | -83.86% |
Benchmark Metrics
VYNE Therapeutics Inc. has an annualized alpha of -38.55%, beta of 0.93, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since January 26, 2018.
- This stock participated in 186.81% of S&P 500 Index downside but only -92.44% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -38.55%
- Beta
- 0.93
- R²
- 0.03
- Upside Capture
- -92.44%
- Downside Capture
- 186.81%
Return for Risk
Risk / Return Rank
VYNE ranks 38 for risk / return — below 38% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for VYNE Therapeutics Inc. (VYNE) and compare them to S&P 500 Index.
| VYNE | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.30 | 2.24 | -2.54 |
Sortino ratioReturn per unit of downside risk | 0.61 | 3.07 | -2.47 |
Omega ratioGain probability vs. loss probability | 1.13 | 1.41 | -0.28 |
Calmar ratioReturn relative to maximum drawdown | -0.41 | 2.93 | -3.34 |
Martin ratioReturn relative to average drawdown | -0.51 | 13.52 | -14.03 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the VYNE Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the VYNE Therapeutics Inc. was 99.99%, occurring on Sep 9, 2025. The portfolio has not yet recovered.
The current VYNE Therapeutics Inc. drawdown is 99.98%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -99.99%Sep 2025 | 7y 5mo | — | 8y 2moMar 2018 - now |
2018 correction2018 | -19.02%Mar 2018 | 1mo 17d | 8d | 1mo 25dFeb 2018 - Mar 2018 |
2018 pullback2018 | -0.70%Jan 2018 | 0s | 3d | 3dJan 2018 - Jan 2018 |
Drawdown Indicators
| VYNE | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.99% | -56.78% | -43.21% |
Max Drawdown (1Y)Largest decline over 1 year | -83.79% | -9.10% | -74.69% |
Max Drawdown (3Y)Largest decline over 3 years | -95.23% | -18.90% | -76.33% |
Max Drawdown (5Y)Largest decline over 5 years | -99.61% | -25.43% | -74.18% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.98% | -0.74% | -99.24% |
Average DrawdownAverage peak-to-trough decline | -93.08% | -10.72% | -82.36% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 67.22% | 1.97% | +65.25% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of VYNE Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how VYNE Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for VYNE relative to other companies in the Biotechnology industry. Currently, VYNE has a P/S ratio of 61.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for VYNE in comparison with other companies in the Biotechnology industry. Currently, VYNE has a P/B value of 1.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with VYNE
Add VYNE Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with VYNE